ILMN · Illumina, Inc.
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jun 25, 2024; bars on opposite sides are not compared.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Free cash flow non-GAAP | $162M | Q2 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net cash provided by operating activities 201M
-39M Purchases of property and equipment
= Free cash flow 162M
|
|||
| Non-GAAP operating margin non-GAAP | 22.5% | Q2 2026 | — |
|
|
|||
| Organic revenue growth non-GAAP | 6.5% | Q2 2026 | — |
| ROW organic revenue growth non-GAAP | 8.1% | Q2 2026 | — |
| Capital expenditures for free cash flow purposes | $38M | Q1 2026 | — |
|
|
|||
| Cash flow provided by operations | $289M | Q1 2026 | — |
|
|
|||
| Cash, cash equivalents and short-term investments | $1.63B | Q4 2025 | — |
| Depreciation and amortization | $270M | Fiscal year 2025 | — |
| Depreciation and amortization expense | $67M | Q4 2025 | — |
| GAAP operating margin | 18.6% | Fiscal year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ILMN
this stock
Illumina, Inc.
|
$28.82B | +45.5% | -0.7% | 35.6 | 5.3% |
|
TMO
Thermo Fisher Scientific Inc.
|
$217.52B | +1.5% | +14.5% | 31.7 | 1.3% |
|
DHR
Danaher Corp /De/
|
$142.32B | -11.6% | +8.5% | 35.9 | 1.7% |
|
NTRA
Natera, Inc.
|
$44.67B | +35.3% | -2.8% | — | 3.0% |
|
IDXX
Idexx Laboratories Inc /De
|
$43.41B | -18.6% | +10.4% | 38.7 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jun 25, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ILMN | +1.6% | +2.3% | +58.4% | -6.9% | +45.5% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +1.2% | -2.2% | +44.6% | -10.9% | +31.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.